Core Viewpoint - The company, MicroTech Medical-B (02235.HK), anticipates significant revenue growth and a return to profitability for the fiscal year ending December 31, 2025, driven by strong product performance and effective management strategies [1] Financial Performance - The company expects revenue for the reporting period to be no less than RMB 650 million, representing an approximate 88.1% increase compared to RMB 345.6 million for the fiscal year ending December 31, 2024 [1] - The projected net profit attributable to the parent company is expected to be no less than RMB 38 million, a turnaround from a loss of RMB 63.1 million for the fiscal year ending December 31, 2024, indicating an increase of RMB 101.1 million [1] Growth Drivers - The revenue growth is primarily attributed to the strong performance of the continuous glucose monitoring system, one of the company's core products [1] - Significant success in expanding into overseas markets, with the LinX continuous glucose monitoring system entering multiple countries, leading to notable growth in international revenue [1] - Enhanced operational efficiency through lean management practices, resulting in a substantial decrease in the proportion of sales and management expenses relative to revenue [1]
微泰医疗-B(02235.HK)：预计2025年实现收入大幅增长，成功扭亏为盈